Global IV Flush Syringe Market - 2022-2029

Market Overview

IV Flush Syringe Market size was valued US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 5.7 % during the forecast period (2022-2029).

IV flush syringes are common medical devices used to clear intravenous lines. Saline flushes are generally safe and well tolerated by patients when administered properly. Millions of patients use it daily to clean intravenous lines. This makes it more likely that medications will be completely absorbed, won't mix inside the tube, and that blood there won't clot. Saline IV flush syringes and heparin IV flush syringes are the two types of IV flush syringes.

Market Dynamics

Innovation in the IV flush syringes is expected to drive market growth.

Double-chamber syringes have been created as a medicine and device combo product to make it easier to reconstitute and administer pharmaceuticals in predefined amounts. Since they frequently call for the delivery of two fluids, one flush solution that has already been prefilled and an empty chamber that needs to be filled with medication, many of the currently available syringes sold for the administration of multiple fluids have not been well welcomed. However, no syringe that enables filling both chambers simultaneously, one for ordinary medication administration and the other for a subsequent catheter flush, has acquired broad popularity. A double-chamber syringe is created to cover this market gap and allow for the filling and delivery of medication and flush solution. Moreover, the novel syringe is expected to make it easier for nurses to implement best clinical practices during intravenous medication administration, such as flushing, cutting down on preparation and administration time, reducing the number of catheter adjustments, and lowering PIVC-related problems. Thus, from the above statements, the market is expected to drive in the forecast period.

Complications associated with IV Flush Syringe are expected to hamper the market growth.

An air embolism develops when one or more air bubbles enter an artery or vein and restrict blood flow. A syringe or IV can inadvertently inject air into a vein. The majority of air embolisms are benign, producing very subtle symptoms or none at all. These typically go away on their own without having any negative effects. However, air embolisms are extremely rare and rarely affect the brain, heart, or lungs. If they do, a heart attack, stroke, or respiratory failure could result.

Moreover, fluid overload and an allergic reaction are two more severe side effects of a sodium chloride flush. Despite being relatively uncommon, both can be fatal and increase recalls of flush syringes. Thus, from the above statements, the market is expected to get hampered in the forecast period.

Industry Analysis

The IV flush syringe market provides in-depth analysis of the market based on various industry factors such as supply chain analysis, pricing analysis etc.

COVID-19 Impact Analysis

The COVID-19 pandemic has positively impacted healthcare systems and the market. Health care professionals, such as pharmacists and nurses, have experienced significant psychological, emotional, and physical effects due to the global COVID-19 pandemic. Moreover, clinical workers must wear additional personal protective equipment (PPE) that might restrict their range of motion and reaction time due to the virus's contagious nature. This raises the likelihood of mistakes occurring when medications are prepared and administered. Utilizing ready-to-administer (RTA) medications is one strategy to ease physicians' workload and minimize complicated drug preparation steps. Prefilled syringes and other RTA items, for instance, can significantly improve productivity while minimizing mistakes and possible patient injury.

In contrast, as of March 21, 2022, the U.S. Food and Drug Administration (FDA) is aware that there are shortages of prefilled intravenous (IV) lock/flush syringes that contain 0.9 percent sodium chloride (saline) in the country. Due to a rise in demand during the COVID-19 public health emergency and subsequent vendor supply chain difficulties, including the permanent discontinuation of some prefilled saline lock/flush syringes, there is a shortage of prefilled 0.9 percent sodium chloride IV lock/flush syringes. Thus, from the above statements, the market is expected to boost in the forecast period.

Segment Analysis

Saline IV Flush Syringe segment is expected to hold the largest market share in IV Flush Syringe market

The saline IV flush syringe segment is expected to dominate in 2021. The segment benefits because the hazards of microbial contamination that arise when doses are drawn up at the ward level are eliminated by the use of prefilled saline syringes. Additionally, the chance of incorrect selection is decreased by the completely labeled nature of prefilled syringes. The time saved by nurses is another important issue. Ad hoc preparation of intravenous dosages incurs costs (including disposables and nurse time) that are frequently disregarded but can pile up in a busy ward. According to one study, using prefilled syringes reduced nursing time by 42% compared to using traditional injection systems.

Further, under the NPSA recommendation, Northampton General Hospital introduced prefilled saline syringes early this year as a part of a broader push to reduce the use of heparin flushes. The NPSA Alert 20, Promoting Safer Use of Injectable Medicines, served as the starting point and contained several action items and suggested actions to increase the safety of injectable medications. Therefore, it has increased the demand for saline IV flush syringes. Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global IV flush syringe market

In 2021, North America accounted for the highest revenue share. The increasing inpatient admissions for chronic diseases, rising surgical procedures, the high adoption of the IV flush syringe, well-established infrastructure and product launches and acquisitions by the region's key market players are some factors the market is expected to boost in the forecast period. For instance, heart disease is the leading cause of death for both sexes and members of most racial and ethnic groups in the United States. Cardiovascular disease claims one life in the United States every 34 seconds. In the United States, heart disease claimed the lives of almost 697,000 people in 2020, accounting for 1 in 5 fatalities. Patients with heart disease who experience an aggravation must be admitted to the hospital and given special care. The strong demand for these syringes is expected to be influenced by this issue.

Moreover, BD (Becton, Dickinson and Company) announced in October 2021 that it had strengthened the US government's access to safe injection devices by boosting production. The public-private cooperation between BD and the Assistant Secretary for Preparedness and Response at the Department of Health and Human Services (HHS) created the new syringe and needle manufacturing lines (ASPR). Thus, from the above statements, the North American region is expected to hold the largest market share in the forecast period.

Competitive Landscape

Major key players in the IV flush syringe market are B. Braun Melsungen AG, R. A. Caldwell Co. Inc., Becton, Dickinson and Company, Cardinal Health, Nipro Corporation, Aquabiliti, Medline Industries, LP, Medefil, Inc., Polymedicure, SteriCare Solutions.

B. Braun Melsungen AG:

Overview:

B. Braun is a German manufacturer of medical and pharmaceutical devices. The B. Braun product line includes 5,000 items, 95 percent of which are manufactured by the company. The company's product portfolio includes infusion, nutrition, pain therapy products, infusion pumps and systems, surgical instruments, suture materials, hip and knee implants, dialysis equipment and accessories, ostomy, disinfection, and wound care products. The company operates its business through five divisions: hospital care, Aesculap, B. Braun Avitum, out-patient market (OPM) and other sales. B. Braun has a presence in 64 countries and develops products in 18 therapy fields of the healthcare industry.

Product Portfolio:

Omniflush with SwabCap: A standard saline intravenous flush syringe with an integrated SwabCap is called an Omniflush with SwabCap. A SwabCap is a luer access valve cap with a 70% isopropyl alcohol disinfection concentration. For the user's convenience, they are incorporated together. The purpose of SwabCap is to serve as a cover for swab-able Luer access valves, shielding them from potential contamination. The SwabCap is a cleaning disinfectant before line access and a physical barrier to contamination between line accesses. SwabCap will disinfect the valve thirty (30) seconds after application and maintains a disinfected valve surface for up to seven (7) days if not removed.

The global IV flush syringe market report would provide an access to an approx. 45+market data table, 40+figures and 160pages.